ImmunityBio (IBRX) Cost of Revenue (2025 - 2026)
ImmunityBio (IBRX) reported Cost of Revenue of $238000.0 for Q1 2026, up 310.34% year-over-year from $58000.0 in Q1 2025, and down 37.7% quarter-over-quarter from $382000.0 in Q4 2025.
ImmunityBio (IBRX) Cost of Revenue (2025 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 2 years of Cost of Revenue data on file, last reported at $238000.0 in Q1 2026.
- Cost of Revenue for Q1 2026 came in at $238000.0, up 310.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $933000.0 (up 1508.62% YoY), and the FY2025 annual result was $753000.0, changed N/A from the prior year.
- Cost of Revenue eased to $238000.0 in Q1 2026 per IBRX's latest filing, from $382000.0 in the prior quarter.
- Over five years, Cost of Revenue peaked at $382000.0 in Q4 2025 and troughed at $58000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | 238,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |